NKGN · As filed with the SEC
NKGen Biotech income statement, by quarter
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Research and development expenses | 1,857 | 1,556† | 2,778 | 3,086 |
| General and administrative expenses | 2,809 | 3,544† | 4,010 | 4,371 |
| Total cost and expenses | 4,666 | 5,100† | 6,788 | 7,457 |
| Loss from operations | (4,666) | (5,100)† | (6,788) | (7,457) |
| Other income (expense): | ||||
| Interest expense (including related party amounts of $237 and $698 for the three months ended March 31, 2025 and 2024, respectively) | (509) | (536)† | (472) | (647) |
| Loss on issuance of financial instruments (including related party amounts of zero and $74 for the three months ended March 31, 2025 and 2024, respectively) | (1,050) | (8,083)† | (3,990) | (13,157) |
| Gain on amendments to financial instruments, net | 0 | (710)† | 999 | (5,222) |
| Change in fair value of financial instruments (including related party amounts of $1,041 and zero for the three months ended March 31, 2025 and 2024, respectively) | 21,575 | (14,932)† | 16,849 | 10,395 |
| Transaction costs expensed | — | — | 0 | — |
| Convertible bridge loans | 160 | — | — | — |
| Other loss, net | 0 | 0† | 0 | 0 |
| Total other income (expense) | 20,016 | — | — | — |
| Net income (loss) before provision for income taxes | 15,350 | (29,361)† | 6,598 | (16,088) |
| Provision for income taxes | 0 | (53)† | 0 | 0 |
| Net income (loss) | 15,350 | (29,414)† | 6,598 | (16,088) |
| Comprehensive income (loss) | — | — | 6,598 | (16,088) |
| Effect of dilutive securities | — | — | (291) | — |
| Convertible promissory notes | (14,879) | — | — | — |
| Senior convertible notes shares | 237 | — | — | — |
| Convertible bridge loans | (138) | — | — | — |
| Convertible promissory note warrants | (4,713) | — | — | — |
| Net loss for diluted earnings per share | (4,143) | — | 6,307 | — |
| Weighted-average common shares outstanding: | ||||
| Basic (in shares) | 45,962,049 | — | 29,133,049 | 24,168,733 |
| Diluted (in shares) | 102,654,719 | — | 41,331,258 | 24,168,733 |
| Net income (loss) per share: | ||||
| Basic (in USD per share) | 0.33 | — | 0.23 | (0.67) |
| Diluted (in USD per share) | (0.04) | — | 0.15 | (0.67) |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.